6-Fluoro-3-isobutyl-1H-indole
![]() |
- $517 - $3230
- Product name: 6-Fluoro-3-isobutyl-1H-indole
- CAS: 1002332-01-5
- MF: C12H14FN
- MW: 191.24
- EINECS:
- MDL Number:MFCD20669007
- Synonyms:6-Fluoro-3-isobutyl-1H-indole;1H-Indole, 6-fluoro-3-(2-methylpropyl)-
4 prices
Selected condition:
Brand
- AccelPharmtech
- Chemenu
- Crysdot
Package
- 1G
- 5G
- ManufacturerAccelPharmtech
- Product numberH0369
- Product description6-fluoro-3-(2-methylpropyl)-1H-Indole 97.00%
- Packaging1G
- Price$1890
- Updated2021-12-16
- Buy
- ManufacturerAccelPharmtech
- Product numberH0369
- Product description6-fluoro-3-(2-methylpropyl)-1H-Indole 97.00%
- Packaging5G
- Price$3230
- Updated2021-12-16
- Buy
- ManufacturerChemenu
- Product numberCM230980
- Product description6-Fluoro-3-isobutyl-1H-indole 95%+
- Packaging1g
- Price$517
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11370168
- Product description6-Fluoro-3-isobutyl-1H-indole 97%
- Packaging1g
- Price$548
- Updated2021-12-16
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
AccelPharmtech | H0369 | 6-fluoro-3-(2-methylpropyl)-1H-Indole 97.00% | 1G | $1890 | 2021-12-16 | Buy |
AccelPharmtech | H0369 | 6-fluoro-3-(2-methylpropyl)-1H-Indole 97.00% | 5G | $3230 | 2021-12-16 | Buy |
Chemenu | CM230980 | 6-Fluoro-3-isobutyl-1H-indole 95%+ | 1g | $517 | 2021-12-16 | Buy |
Crysdot | CD11370168 | 6-Fluoro-3-isobutyl-1H-indole 97% | 1g | $548 | 2021-12-16 | Buy |
Properties
Boiling point :306.8±22.0 °C(Predicted)
Density :1.109±0.06 g/cm3(Predicted)
pka :16.70±0.30(Predicted)
Density :1.109±0.06 g/cm3(Predicted)
pka :16.70±0.30(Predicted)
Safety Information
Symbol(GHS): |
![]() |
|||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | |||||||||||||||||||||||||||||||||||
Hazard statements: |
|
|||||||||||||||||||||||||||||||||||
Precautionary statements: |
|